Know Cancer

or
forgot password

Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer


N/A
19 Years
N/A
Open (Enrolling)
Female
Breast Cancer

Thank you

Trial Information

Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer


Inclusion Criteria:



- Patients are eligible for the study if they are over 18 years of age, identify their
ancestry as Jewish (both Sephardic and Ashkenazi Jews are eligible), have or have had
a diagnosis of breast cancer, and are able to give informed consent.

- Relatives, age 18 or older, of the patients who meet eligibility criteria above and
are found to have a specific BRCA1 or BRCA2 mutation if they are able to give
informed consent.

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

to further characterize inherited predisposition to breast cancer mediated by specific BRCA alleles among Jewish women.

Outcome Time Frame:

Conclusion of the study

Safety Issue:

No

Principal Investigator

Kenneth Offit, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

97-029

NCT ID:

NCT00590109

Start Date:

March 1997

Completion Date:

December 2013

Related Keywords:

  • Breast Cancer
  • Breast Cancer
  • Jewish
  • BRCA1
  • BRCA2
  • 97-029
  • Breast Neoplasms

Name

Location
Memorial Sloan Kettering Cancer Center New York, New York  10021